EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate

Ondřej Fiala iD, Petr Hošek, Hana Korunková, Milan Hora iD, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti iD, Jindřich Fínek

Cancer Medicine · 2024

DOI: 10.1002/cam4.6853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ondřej Fiala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Abiraterone Acetate, Nitriles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Research Fund of University Hospital Pilsen, European Union's Horizon 2020, European Union - Next Generation EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic co‐morbidities requiring use of various concomitant medications. In the present study, we focused on impact of concomitant antihypertensive medication on the outcomes of mCRPC patients treated with ENZ or ABI.

Methods

In total, 300 patients were included and their clinical data were retrospectively analyzed.

Results

Angiotensin‐converting enzyme inhibitors (ACEIs) represented the only concomitant medication significantly associated with survival. The median radiographic progression‐free survival (rPFS) and overall survival (OS) for patients using ACEIs were 15.5 and 32.3 months compared to 10.7 and 24.0 months for those not using ACEIs ( p = 0.0053 and p = 0.0238, respectively). Cox multivariable analysis revealed the use of ACEIs a significant predictive factor for both rPFS (HR = 0.704, p = 0.0364) and OS (HR = 0.592, p = 0.0185).

Conclusion

The findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPhenylthiohydantoinAbiraterone AcetateNitrilesBenzamidesAntihypertensive AgentsHumansMaleAgedRetrospective StudiesAged, 80 and overMiddle AgedTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsProgression-Free SurvivalAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

abiraterone acetateangiotensin‐converting enzyme inhibitorsantihypertensivescastration‐resistant prostate cancercomedicationenzalutamidenovel hormonal therapies

Substanzen

PhenylthiohydantoinenzalutamideAbiraterone AcetateNitrilesBenzamidesAntihypertensive AgentsAngiotensin-Converting Enzyme Inhibitors

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • 2nd Department of Internal Medicine, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Surgery, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.

ORCID-Profile: Ondřej Fiala, Milan Hora, Sebastiano Buti

Förderung

  • Institutional Research Fund of University Hospital Pilsen
  • European Union's Horizon 2020
  • European Union - Next Generation EU
  • Charles University Research Fund

Zitieren

APA

Fiala, O., Hošek, P., Korunková, H., Hora, M., Kolář, J., Šorejs, O., Topolčan, O., Filipovský, J., Liška, V., Santoni, M., Buti, S., & Fínek, J. (2024). Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer Medicine. https://doi.org/10.1002/cam4.6853

Vancouver

Fiala O, Hošek P, Korunková H, Hora M, Kolář J, Šorejs O, et al. Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate. Cancer Medicine. 2024. doi:10.1002/cam4.6853

BibTeX
@article{Fiala2024,
  author = {Fiala, Ondřej and Hošek, Petr and Korunková, Hana and Hora, Milan and Kolář, Jiří and Šorejs, Ondřej and Topolčan, Ondřej and Filipovský, Jan and Liška, Václav and Santoni, Matteo and Buti, Sebastiano and Fínek, Jindřich},
  title = {Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6853}
}
Kostenlos starten →